This pre-planned meta-analysis shows that similar improvements in HbA1c can be achieved with fewer hypoglycaemic episodes, particularly nocturnal episodes, with IDeg than with IGlar across a broad spectrum of patients with diabetes (particularly T2DM patients), and insulin regimens. The gene discussed is INS; the disease is type 2 diabetes mellitus.